NCT04384497View on ClinicalTrials.gov

Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 7, 2020

Primary Completion Date

June 1, 2020

Study Completion Date

December 1, 2020

Conditions
COVID-19
Interventions
BIOLOGICAL

SARS-CoV-2 convalescent plasma

Treatment with convalescent plasma (200ml, up to a maximum of 7 CP infusions). Plasma from consenting individuals who have recovered from SARS-CoV-2 infection.

Trial Locations (2)

14186

Karolinska University Hospital, Stockholm

18257

Danderyd Hospital, Danderyd

All Listed Sponsors
collaborator

Danderyd Hospital

OTHER

collaborator

Karolinska University Hospital

OTHER

collaborator

Karolinska Institutet

OTHER

lead

Joakim Dillner

OTHER

NCT04384497 - Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study | Biotech Hunter | Biotech Hunter